I am thrilled to announce that today Arsenal Biosciences, a programmable cell therapy company, launched with $85 million Series A funding. As well as seeding the company, Westlake Village BioPartners is a significant contributor to the Series A funding round. The company will integrate technologies such as CRISPR-based genome engineering, scaled and high throughput target identification, synthetic biology, and machine learning. Read more… https://lnkd.in/e8mmXch #celltherapy #arsenal #highthroughput #westlakevillage #seeding #programmable #biosciences #syntheticbiology #genome …see more